Global Hospital-Acquired Infection Control Market 2017-2021

  • ID: 4328327
  • Report
  • Region: Global
  • 94 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • 3M
  • AbbVie
  • AstraZeneca
  • BD
  • Cepheid
  • GlaxoSmithKline
  • MORE
About Hospital-Acquired Infection Control

HAIs, which are also called nosocomial infections, refer to a collection of conditions that a patient may develop when being treated in hospitals or other healthcare facilities. Modern healthcare settings use multiple devices to treat patients. These can be breeding grounds for microorganisms, which can have adverse effects on patient health. HAIs have caused a significant cost burden on patients and healthcare facilities.

The analysts forecast the global hospital-acquired infection control market to grow at a CAGR of 4.81% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global hospital-acquired infection control market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of HAI products.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
The report, Global Hospital-Acquired Infection Control Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • AstraZeneca
  • GlaxoSmithKline
  • Merck
  • Pfizer
Other prominent vendors
  • 3M
  • Abbott Laboratories
  • AbbVie
  • Advanced Sterilization Products
  • Alere
  • Bayer
  • BD
  • bioMérieux
  • Cepheid
  • Getinge Group
  • Hoffmann La-Roche
  • Synergy Health
  • Xenex
Market drivers
  • Increasing innovative measures to prevent HAIs
  • For a full, detailed list, view the full report
Market challenges
  • Emergence of antibiotic resistance
  • For a full, detailed list, view the full report
Market trends
  • Emergence of innovative techniques to remove biofilms
  • For a full, detailed list, view the full report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 3M
  • AbbVie
  • AstraZeneca
  • BD
  • Cepheid
  • GlaxoSmithKline
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
  • Overview
PART 05: Market landscape
  • Overview
  • Market size and forecast
  • Five forces analysis
PART 06: Segmentation by infection type
  • Overview
  • CAUTIs
  • SSIs
  • CLABSIs
  • Respiratory infections
PART 07: Segmentation by end-user
  • Overview
  • Hospitals and ICUs
  • Outpatient care centers
  • LTCFs
  • Others
PART 08: Segmentation by geography
  • Overview
  • Americas
  • EMEA
  • APAC
PART 09: Decision framework

PART 10: Drivers and challenges
  • Market drivers
  • Market challenges
PART 11: Market trends
  • Emergence of innovative techniques to remove biofilms
  • Decrease in regulatory approvals of antibiotics
  • Focus on early diagnosis and preventive medicine
  • Cost burden of HAIs on patients and hospitals
PART 12: Vendor landscape
  • Competitive scenario
PART 13: Key vendor analysis
  • AstraZeneca
  • GlaxoSmithKline
  • Merck
  • Pfizer
  • Other prominent vendors
PART 14: Appendix
  • List of abbreviations
List of Exhibits
Exhibit 01: Prevention, diagnosis, and treatment methods of HAIs
Exhibit 02: Global HAI control market: Overview 2016-2021
Exhibit 03: Global HAI control market 2016-2021 ($ million)
Exhibit 04: Factors impacting global HAI control market
Exhibit 05: Five forces analysis
Exhibit 06: Global HAI control market: Segmentation by infection type 2016 and 2021 (% share)
Exhibit 07: Global HAI control market for CAUTIs 2016-2021 ($ million)
Exhibit 08: Global HAI control market for SSIs 2016-2021 ($ million)
Exhibit 09: Global HAI control market for CLABSIs 2016-2021 ($ million)
Exhibit 10: Global HAI control market for respiratory infections 2016-2021 ($ million)
Exhibit 11: Global HAI control market: Segmentation by end-user 2016 and 2021 (% share)
Exhibit 12: Global HAI control market: Overview of segmentation by end-user
Exhibit 13: Global HAI control market by hospitals and ICUs 2016-2021 ($ million)
Exhibit 14: Global HAI control market by outpatient care centers 2016-2021 ($ million)
Exhibit 15: Global HAI control market by LTCFs 2016-2021 ($ million)
Exhibit 16: Global HAI control market by others 2016-2021 ($ million)
Exhibit 17: Global HAI control market: Segmentation by geography 2016-2021 (% share)
Exhibit 18: Global HAI control market: Overview of segmentation by geography
Exhibit 19: HAI control market in Americas: Overview
Exhibit 21: HAI control market in Americas 2016-2021 ($ million)
Exhibit 22: HAI control market in EMEA: Overview
Exhibit 24: HAI control market in EMEA 2016-2021 ($ million)
Exhibit 25: HAI control market in APAC: Overview
Exhibit 27: HAI control market in APAC 2016-2021 ($ million)
Exhibit 28: Factors contributing to infections among aging people
Exhibit 29: Annual cost of various types of HAIs (% share)
Exhibit 30: Infection preventionists: Roles in preventing HAIs
Exhibit 31: Types and number of positions for infection preventionists in US
Exhibit 32: Discovery of antibiotics 1900-2010
Exhibit 33: Drugs for HAIs in clinical development
Exhibit 34: Strategic success factors for vendors
Exhibit 35: AstraZeneca: Profile
Exhibit 36: AstraZeneca: Strength analysis
Exhibit 37: AstraZeneca: Strategy assessment
Exhibit 38: AstraZeneca: Opportunity assessment
Exhibit 39: GlaxoSmithKline: Profile
Exhibit 40: GlaxoSmithKline: Strength analysis
Exhibit 41: GlaxoSmithKline: Strategy assessment
Exhibit 42: GlaxoSmithKline: Opportunity assessment
Exhibit 43: Merck: Profile
Exhibit 44: Merck: Strength analysis
Exhibit 45: Merck: Strategy assessment
Exhibit 46: Merck Group opportunity assessment
Exhibit 47: Pfizer: Profile
Exhibit 48: Pfizer: Strength analysis
Exhibit 49: Pfizer: Strategy assessment
Exhibit 50: Pfizer: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • 3M
  • AbbVie
  • AstraZeneca
  • BD
  • Cepheid
  • GlaxoSmithKline
  • MORE
New Report Released: - Global Hospital-Acquired Infection Control Market 2017-2021

The author of the report recognizes the following companies as the key players in the global hospital-acquired infection control market: AstraZeneca, GlaxoSmithKline, Merck, and Pfizer.

Other Prominent Vendors in the market are: 3M, Abbott Laboratories, AbbVie, Advanced Sterilization Products, Alere, Bayer, BD, bioMérieux, Cepheid, Getinge Group, Hoffmann La-Roche, Synergy Health, and Xenex.

Commenting on the report, an analyst from the research team said: “One trend in the market is emergence of innovative techniques to remove biofilms. Biofilm refers to a collective layer of microorganisms that can form on the surface of a medical device or on any other area where a biological activity takes place. These layers attach to both biotic and abiotic surfaces. Hence, they can be found at the sites of HAIs.”

According to the report, one driver in the market is increasing innovative measures to prevent HAIs. With increasingly complex pathogens emerging in healthcare facilities and these microbes developing multiple antibiotic resistance, hospitals must use innovative methods to combat HAIs, which is a significant cost burden on the healthcare systems of countries. For instance, HAI infections cost approximately $35 billion annually in the US. Hence innovative measures are required to reduce the incidence of HAIs. The use of ultraviolet (UV) radiation to systematically disinfect hospitals is an innovative approach to control the prevalence of HAIs.

Further, the report states that one challenge in the market is emergence of antibiotic resistance. Antibiotic resistance refers to a microorganism becoming resistant to multiple antibiotics as it modifies itself when exposed to antimicrobial drugs. Microorganisms that develop resistance to antibiotics are referred to as superbugs. Improper hospital hygiene, unwanted or increased use of antibiotics, and emergence of genetic elements that adapt and enhance bacterial resistance mechanisms are the primary causes of antibiotic resistance.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • AstraZeneca
  • GlaxoSmithKline
  • Merck
  • Pfizer
  • 3M
  • Abbott Laboratories
  • AbbVie
  • Advanced Sterilization Products
  • Alere
  • Bayer
  • BD
  • bioMérieux
  • Cepheid
  • Getinge Group
  • Hoffmann La-Roche
  • Synergy Health
  • Xenex
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll